ObsEva SA (OBSV)

$ 2.65
+0.04 (+1.53%)
Symbol OBSV
Price $ 2.65
Beta 0.740
Volume Avg. 1.88M
Market Cap 0.21B
Shares () -
52 Week Range 1.855-5.55
1y Target Est -
DCF Unlevered OBSV DCF ->
DCF Levered OBSV LDCF ->
ROE -269.94% Strong Sell
ROA -86.24% Strong Sell
Operating Margin -
Debt / Equity 128.67% Buy
P/E -
P/B 4.83 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest OBSV news

Dr. Ernest Loumaye
Nasdaq Global Select

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. It also is developing OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company was founded in 2012 and is headquartered in Geneva, Switzerland.